Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tedizolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hetero Gets CDSCO Panel Nod to Study Tedizolid Phosphate for Bacterial Skin Infections
Details : Tedizolid phosphate is an oxazolidinone-class antibacterial drug indicated in adult patients for the treatment of acute bacterial skin and skin structure infections.
Product Name : Tedizolid Phosphate-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 16, 2024
Lead Product(s) : Tedizolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Hetero announced today that it has received the manufacturing and marketing approval for the investigational antiviral medicine ‘Remdesivir’ from the Drug Controller General of India (DCGI) for the treatment of Covid-19.
Product Name : Covifor
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 21, 2020
Lead Product(s) : Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
